The microenvironment of the tumour - Host interface

Nature

Volumn 411, Issue 6835, 2001, Pages 375-379

  Liotta, Lance A ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; ENZYMES; PATHOLOGY; PATIENT TREATMENT; TUMORS;

CANCER AETIOLOGY;

TISSUE;

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANTIFIBROTIC AGENT; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CAFFEIC ACID PHENETHYL ESTER; CELL ENZYME; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; PIRFENIDONE; SQUALAMINE; SULINDAC SULFIDE; VASCULOTROPIN ANTIBODY;

CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; EXTRACELLULAR MATRIX; HOST; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; STROMA CELL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; CELL DIVISION; CELL MOVEMENT; CELL SURVIVAL; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STROMAL CELLS;

EID: 0035902141     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35077241     Document Type: Review

References (65)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Park, C. C., Bissell, M. J. & Barcellos-Hoff, M. H. The influence of the microenvironment on the malignant phenotype. Mol. Med. Today 6, 324-329 (2000).
3. Brown, L. F. et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 5, 1041-1056 (1999).
4. Wernert, N. The multiple roles of tumor stroma. Virchows Arch. 430, 433-443 (1997).
5. Aboseif, S., El-Sakka, A., Young, P. & Cunha, G. Mesenchymal programming of adult human epithelial differentiation. Differentiation 65, 113-118 (1999).
6. Vaccariello, M., Javaherian, A., Wang, Y., Fusenig, N. E. & Garlick, J. A. Cell interactions control the fate of malignant keratinocytes in an organitypic model of early neoplasia. J. Invest. Dermatol. 113, 384-391 (1999).
7. Fidler, I. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother. Pharmacol. 43, 3-10 (1999).
8. Nilsson, E. & Skinner, M. K. Cellular interactions that control primordial follicle development and folliculogenesis. J. Soc. Gynecol. Invest. 8, S17-S20 (2001).
9. Li, Y., Liu, W., Hayward, S. W., Cunha, G. & Baskin, L. S. Plasticity of the urothelial phenotype: effects of gastro-intestinal mesenchyme/stroma and implications for urinary tract reconstruction. Differentiation 66, 126-135 (2000).
10. Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011 (1999).
11. Liotta, I., A., Steeg, P. S. & Stetler-Stevension, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327 (1991).
12. Kohn, E. C. & Liotta, L. A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 55, 1856-1862 (1995).
13. Stromblad, S. & Cheresh, D. A. Integrins, angiogenesis and vascular cell survival. Chem. Biol. 3, 881-885 (1996).
14. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-2571 (2000).
15. Tomakidi, P. et al. Defects in the basement membrane and hemidesmisomes structure correlate with malignant phenotype and stromal interactions in HaCaT-Ras xenografts. Differentiation 64, 263-275 (1999).
16. Guidi, A. J. et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80, 1945-1953 (1997).
17. Lee, A. H., Dublin, E. A. & Bobrow, L. G. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. J. Pathol. 187, 285-290 (1999).
18. Gilead, A. & Neeman, M. Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice. Neoplasia 1, 226-230 (1999).
19. Airola, K. & Fusenig, N. E. Differential stromal regulation of MMP-1 expression in benign and malignant keratinocytes. J. Invest. Dermatol. 116, 85-92 (2000).
20. Sternlicht, M. D. et al. The stromal proteinase MMP-3/stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137-146 (1999).
21. Mehdi, A. et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med. 6, 100-106 (2000).
22. Werb, Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91, 439-442 (1997).
23. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000).
24. Bowden, E., Barth, M., Thomas, D., Glazer, R. & Mueller, S. An invasion related complex of cortactin, paxillin, and PKCμ associates with invadopodia at sites of extracellular matrix degradation. Oncogene 18, 4440-4449 (1999).
25. Nakahara, H. et al. Transmembrane/cytoplasmic domain mediated membrane type 1-matrix metalloproteinase docking to invadopodia is required for cell invasion. Proc. Natl Acad. Sci. USA 94, 7959-7964 (1997).
26. Hoegy, S., Oh, H.-R., Corcoran, M. & Stetler-Stevemon, W. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J. Biol. Chem. 276, 3203-3214 (2001).
27. Andreasen, P., Kioller, L., Christensen, I., & Duffy, M. The urokinase type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72, 1-22 (1997).
28. Fashena, S. & Thomas, S. M. Signaling by adhesion receptors. Nature Cell Biol. 2, E225-E229 (2000).
29. Braga, V. The crossroads between cell-cell adhesion and motility. Nature Cell Biol. 2, E182-E184 (2000).
30. Jo, M. et al. Cross talk bet ween epidermal growth factor receptor and c-Met signal pathways in transformed cells. J. Biol. Chem. 275, 8806-8811 (2000).
31. Varner, J. A. & Cheresh, D. A. Integrins and cancer. Curr. Opin. Cell Biol. 8, 724-730 (1996).
32. Roberts, A. B., McCune, B. K. & Sporn, M. B. TGF-β: regulation of extracellular matrix. Kidney Int. 41, 557-559 (1992).
33. Varner, J. A., Brooks, P. C. & Cheresh, D. A. The integrin αvβ3: angiogenesis and apoptosis. Cell Adhes. Comm. 3, 367-374 (1995).
34. Fukai, F. et al. Release of biologically activities from quiescent fibronectin by conformational change and limited proteolysis by matrix metalloproteinases. Biochemistry 34, 11453-11459 (1995).
35. Davis, G. E. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem. Biophys. Res. Commun. 182, 1025-1031 (1992).
36. Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127 (2000).
37. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
38. Frisch, S. M., Vuori, K., Ruoslahti, F., & Chan-Hui, P. Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol. 134, 793-799 (1996).
39. Frisch, S. M. & Ruoslahti, E. Integrins and anoikis. Curr. Opin. Cell Biol. 9, 701-706 (1997).
40. Cantley, L. & Pawson, T. Cell regulation. Curr. Opin. Cell Biol. 13, 121-124 (2001).
41. Dusko, I. et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377, 539-544 (1995).
42. Xue, L., Murray, J. H. & Tolkovsky, A. M. The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons. J. Biol. Chem. 275, 8817-8824 (2000).
43. Chen, H., Chan, P., Tang, M., Cheng, C. & Chang, T. Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation. J. Biol. Chem. 273, 25777-25782 (1998).
44. Totsukawa, G. et al. Distinct roles of ROCK and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J. Cell Biol. 150, 797-806 (2000).
45. Liotta, L. A. & Petricoin, E. F. Molecular profiling of human cancer. Nature Genet. Rev. 1, 48-56 (2000).
46. St. Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197-1202 (2000).
47. Paweletz, C. P. et al. Reverse phase protein microarrays which capture disease progression shown activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989 (2001).
48. l. Clin. Cancer Res. 6, 3056-3061 (2000).
49. Kohn, F. C. et al. Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl Acad. Sci. USA 92, 1307-1311 (1995).
50. Masiero, L., Lapidos, K. A., Ambudkar, I. &. Kohn, F. C. Regulation of the RhoA pathway in human endothelial cell spreading on type IV collagen: role of calcium influx. J. Cell. Sci. 112, 3205-3213 (1999).
51. Weyant, M. J., Carothers, A. M., Bertangnolli, M. E. & Bertagnolli, M. M. Colon cancer chemopreventative drugs modulate integrin-mediated signaling pathways. Clin. Cancer Res. 6, 949-956 (2000).
52. Brown, P. D. & Giavazzi, R. Matrix melalloproteinase inhibition: a review of anti-tomour activity. Annals Oncol. 6, 967-974 (1995).
53. Rowinsky, E. et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignances. J. Clin. Oncol. 18, 178-186 (2000).
54. Brooks, P. C. et al. Anti-integrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822 (1995).
55. Bonfoco, E., Chen, W., Paul, R., Cheresh, D. A. & Cooper, N. R. β1 integrin antagonism on adherent, differentiated human neuroblastoma cells triggers an apoptotic signaling pathway. Neuroscience 101, 1145-1152 (2000).
56. Lode, H. N. et al. Synergy between an antiangiogenic integrin α, antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc. Natl Acad. Sci. USA 96, 1591-1596 (1999).
57. Kohl, N. E. Farnesyltransferase inhibitors. Preclinical development. Ann. NY Acad. Sci. 686, 91-102 (1997).
58. Sills, A. K. et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58, 2784-2792 (1998).
59. Kohn, E. C. et al. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors. potential efficacy of the combination, and demonstration of pharmacokinetic interaction. Clin. Cancer Res. (in the press).
60. Yuan, Z., Q. et al. Frequent activation of AKT2 and induction of apoptasis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19, 2324-2330 (2000).
61. Perrotte, P. et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257-265 (1999).
62. Iyer, S., Gurujeyalakshimi, G. & Giri, S. N. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Therapeut. 291, 367-373 (1999).
63. Fang, X. et al. Lysophospholipid growth factors in the initiation, progression, metastases and management of ovarian cancer. Ann. NY Acad. Sci. 905, 188-208 (2000).
64. Shayesteh, L. et al. P1K3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21, 99-102 (1999).
65. Furui, T. et al. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin. Cancer Res. 5, 430-4318 (1999).